A correction has been applied to this article in:
Corrigendum: Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy
by Velayutham NK, Thamaraikani T, Wahab S, Khalid M, Ramachawolran G, Abullais SS, Wong LS, Sekar M, Gan SH, Ebenezer AJ, Ravikumar M, Subramaniyan V, Mat Rani NNI, Wu YS and Jeyabalan S (2023). Front. Pharmacol. 14:1150270. doi: 10.3389/fphar.2023.1150270
Due to a production error, there was an error in affiliation 4. Instead of “Department of Foundation, Georgetown, Pulau Pinang, Malaysia,” it should be “Department of Foundation, RCSI & UCD Malaysia Campus, George Town, Pulau Pinang, Malaysia.”
The publisher apologizes for this mistake. The original version of this article has been updated.
Keywords: benzylisoquinoline alkaloids, stylopine, MG-63, osteosarcoma, VEGFR2
Citation: Frontiers Production Office (2023) Erratum: Stylopine: A potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy. Front. Pharmacol. 14:1213155. doi: 10.3389/fphar.2023.1213155
Received: 27 April 2023; Accepted: 27 April 2023;
Published: 05 May 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 and Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org